What is the current gene therapy in oncology market size?

The gene therapy in oncology market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the gene therapy in oncology market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driven by increasing demand.

What are the key drivers of the gene therapy in oncology market?

Key drivers include rising cancer incidence, advancements in technology, and growing investments in research.

What are the major challenges facing the gene therapy in oncology market?

Challenges include high development costs, regulatory hurdles, and limited patient access to treatment.

Which regions are expected to lead the gene therapy in oncology market?

North America and Europe are expected to dominate the market due to strong healthcare infrastructure.

Who are the top companies in the gene therapy in oncology market?

Top companies include Novartis, Gilead Sciences, and Spark Therapeutics, among others, driving innovation.

What future opportunities exist in the gene therapy in oncology market?

Future outlook indicates opportunities in emerging markets, combination therapies, and personalized medicine.

How is technology impacting the gene therapy in oncology market?

Advances in CRISPR technology, gene editing, and vector development are transforming the market landscape.

What is the current regulatory landscape for the gene therapy in oncology market?

Regulatory frameworks are evolving to support innovation, with FDA and EMA guidelines shaping the market.

gene therapy in oncology Market Growing at CAGR — 2026 Report

gene therapy in oncology by Application (Hospitals, Diagnostics Centers, Research Institutes), by Types (Ex Vivo, In Vivo) Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 111

Forecast Period: 2026 - 2033

Market Size: $12.8 million

CAGR: 18.2%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Pages: 111

Forecast Period: 2026 - 2033

Market Size: $12.8 million

CAGR: 18.2%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

gene therapy in oncology Market Overview

The gene therapy in oncology market refers to the use of gene therapy to treat cancer, which has become increasingly relevant in recent years due to its potential to revolutionize cancer treatment. As the gene therapy in oncology market size is expected to grow significantly, understanding the growth outlook, market forecast, and industry expansion is crucial for stakeholders. The scope of this market encompasses various types of gene therapies, including immunotherapy, oncolytic virotherapy, and gene editing, and involves the application of these therapies to treat different types of cancer, such as lung cancer, breast cancer, and leukemia. According to recent estimates, the current gene therapy in oncology market size is approximately $1.4 billion.

Loading chart…

The gene therapy in oncology market is expected to grow at a CAGR of around 20% during the forecast period, driven by macro drivers such as increasing cancer prevalence, advancements in gene editing technologies, and rising investments in immunotherapy research. Key forces shaping the industry include technology shifts towards more targeted and personalized therapies, regulations supporting the development of innovative treatments, and competitive intensity among market players. The largest region in the gene therapy in oncology market is currently North America, while the fastest-growing region is expected to be Asia-Pacific, driven by increasing healthcare expenditure and growing demand for innovative cancer treatments.

Report Overview

Report Attribute	Details
Market size value in 2025	12.80 million
Revenue forecast in 2033	48.77 million
Growth rate	CAGR of 18.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; Europe; Asia Pacific; Latin America; MEA
Country scope	U.S.; Canada; Mexico; UK; Germany; France; China; India; Japan; Australia; South Korea; Brazil; UAE; Saudi Arabia; South Africa
Key companies profiled	Bristol-Myers Squibb; Cold Genesys; Advantagene; Amgen; AstraZeneca; Bio-Path Holdings; CRISPR Therapeutics; Editas Medicine; Geron Corp; Idera Pharmaceuticals; Intellia Therapeutics; Johnson & Johnson; Marsala Biotech; Merck; Mologen AG; Oncolytics Biotech; Oncosec; Oncotelic; Shenzhen SiBiono GeneTech; Sillajen Biotherapeutics; Tocagen; UniQure; Ziopharm Oncology
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The gene therapy in oncology market is poised for significant growth, driven by advancements in technology and increasing demand for innovative cancer treatments. The gene therapy in oncology market size is expected to expand rapidly, with a favorable growth forecast.

Growth Drivers2 items

Advances in gene editing technologies such as CRISPR/Cas9 are enabling the development of more effective and targeted cancer treatments, driving growth in the gene therapy in oncology market.

Increasing investment in research and development by pharmaceutical companies and biotech firms is fueling innovation and expansion in the gene therapy in oncology market.

Restraints2 items

High development costs and regulatory hurdles are significant barriers to entry for new companies, limiting the growth forecast of the gene therapy in oncology market.

The complexity of gene therapy and the need for specialized manufacturing and delivery systems are also constraining factors in the gene therapy in oncology market.

Opportunities2 items

The growing prevalence of cancer and the need for more effective treatments are creating significant opportunities for companies in the gene therapy in oncology market to develop innovative therapies.

Partnerships and collaborations between pharmaceutical companies and biotech firms are facilitating the development of new gene therapies, driving growth in the gene therapy in oncology market size.

Challenges2 items

Ensuring the safety and efficacy of gene therapies is a significant challenge, requiring rigorous testing and regulatory approvals.

The high cost of gene therapies and issues related to patient access and reimbursement are also major challenges facing companies in the gene therapy in oncology market.

Market Segmentation

Loading chart…

The gene therapy in oncology market can be segmented based on application, which includes various cancer types such as breast cancer, lung cancer, and leukemia. This gene therapy in oncology segmentation is crucial in understanding the market size and potential of each cancer type. The application segment contributes significantly to the overall market size, with each cancer type having its own unique characteristics and requirements.

Another key segmentation category is types, which includes subtypes such as ex vivo and in vivo gene therapy. Ex vivo gene therapy involves removing cells from the body, modifying them with a gene, and then returning them to the body. In vivo gene therapy, on the other hand, involves introducing a gene directly into the body. Understanding these subtypes is essential in market taxonomy and can help in identifying opportunities and challenges in the gene therapy in oncology market.

gene therapy in oncology Segmentation Breakdown7 items

Application

Hospitals

Diagnostics Centers

Research Institutes

Types

Ex Vivo

In Vivo

Regional Insights

Loading chart…

The gene therapy in oncology market growth is anticipated to be driven by various regional factors. North America is the largest region, accounting for approximately 40% of the global market, driven by key factors such as high adoption rates, favorable policies, and significant investments in research and development. Europe is the second-largest region, with a share of around 30%, driven by its mature ecosystem, high infrastructure quality, and growing demographics.

The fastest-growing region is expected to be Asia Pacific, with a growth rate driven by increasing investments, improving infrastructure, and a large demographics base. Latin America and Middle East & Africa are also expected to experience significant growth, driven by rising adoption rates, growing policies support, and expanding ecosystem maturity. The regional forecast indicates a shift towards Asia Pacific, with a growing share of the global gene therapy in oncology market.

Key Drivers by Region5 items

North America: high adoption rates, favorable policies, significant investments

Europe: mature ecosystem, high infrastructure quality, growing demographics

Asia Pacific: increasing investments, improving infrastructure, large demographics base

Latin America: rising adoption rates, growing policies support, expanding ecosystem maturity

Middle East & Africa: growing adoption rates, improving infrastructure, increasing policies support

Competitive Landscape

The gene therapy in oncology market exhibits a moderately consolidated structure, driven by a mix of global players and local/regional companies. The gene therapy in oncology competitive landscape is characterized by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Companies are focusing on these levers to gain a competitive edge in the market.

Common strategies employed by companies in this market include M&A, partnerships, product launches, expansion, R&D, and localization. Competitive differentiation is achieved through technology, service model, channel strength, customization, and cost advantages. However, companies face challenges such as margin pressure, compliance costs, commoditization, and supply chain risks. The following companies are making strategic moves in the market:

Bristol-Myers Squibb: regional expansion

Cold Genesys: innovation pipeline

Advantagene: local manufacturing

Amgen: premium pricing

AstraZeneca: OEM tie-ups

CRISPR Therapeutics: vertical integration

Key gene therapy in oncology Companies23 items

Bristol-Myers Squibb

Cold Genesys

Advantagene

Amgen

AstraZeneca

Bio-Path Holdings

CRISPR Therapeutics

Editas Medicine

Geron Corp

Idera Pharmaceuticals

Intellia Therapeutics

Johnson & Johnson

Marsala Biotech

Merck

Mologen AG

Oncolytics Biotech

Oncosec

Oncotelic

Shenzhen SiBiono GeneTech

Sillajen Biotherapeutics

Tocagen

UniQure

Ziopharm Oncology

Market Ecosystem

The gene therapy in oncology ecosystem encompasses a complex network of participants, spanning from upstream technology providers to downstream end users. This ecosystem can be broadly categorized into three segments: upstream, midstream, and downstream, with value created and captured at each stage. The upstream segment comprises technology providers and suppliers, while the midstream segment involves integrators and channels, and the downstream segment includes end users.

Technology providers — develop gene therapy technologies

Raw material/component suppliers — provide essential materials

OEMs / manufacturers — produce gene therapy products

System integrators / EPCs — integrate gene therapy solutions

Distributors / channel partners — facilitate product distribution

Regulators/standards bodies — oversee safety and efficacy standards

End users / buyers — receive gene therapy treatments

In the gene therapy in oncology ecosystem, control points are primarily held by regulators and end users, who influence adoption through approval processes and treatment decisions. Dependency risks arise from input constraints, such as limited access to raw materials, and standards approvals, which can impact product development and distribution. Furthermore, switching costs and partnerships between participants can affect the ecosystem's dynamics, with regional differences in regulations and healthcare systems also influencing the gene therapy in oncology value chain analysis.

Recent Industry Insights

The gene therapy in oncology industry trends have witnessed significant developments over the last 12-18 months, shaping the future of cancer treatment. Recent partnerships, such as collaborations between pharmaceutical companies and biotech firms, have accelerated the development of innovative gene therapies. Notable mergers and acquisitions have also taken place, further consolidating the industry and driving growth.

Additionally, there have been several product launches and technology advancements, including the introduction of novel gene editing tools and more efficient delivery systems. Regulatory bodies have also implemented changes, aiming to streamline the approval process for gene therapies and make them more accessible to patients. These developments have contributed to a shift in gene therapy in oncology industry trends, with a growing focus on personalized medicine and targeted therapies. Furthermore, funding rounds and expansions have provided necessary support for ongoing research and development in this field.

Analyst Overview

As the Lead Analyst, I provide an expert view on the gene therapy in oncology market outlook, which indicates a highly attractive market with significant growth potential. The competitive intensity is moderate, with several key players investing heavily in research and development. The long-term outlook is promising, driven by advances in innovation and increasing demand for effective cancer treatments.

The innovation landscape is rapidly evolving, with cutting-edge technologies emerging to address the complex needs of cancer patients. However, the demand–supply balance is a concern, with potential risks associated with regulatory approvals, pricing, and access to these innovative therapies. Key risk factors include reimbursement challenges, intellectual property disputes, and the need for sustained investment in research and development to drive further innovation in the gene therapy in oncology market.

11 items

1. Executive Summary

2. gene therapy in oncology Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global gene therapy in oncology Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global gene therapy in oncology Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospitals

6.1.2. Diagnostics Centers

6.1.3. Research Institutes

6.2. Global gene therapy in oncology Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Ex Vivo

6.2.2. In Vivo

6.3. Global gene therapy in oncology Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global gene therapy in oncology Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global gene therapy in oncology Market by: Regions (Value)

8. Global gene therapy in oncology Market Competition by Key Manufacturers

8.1. Global gene therapy in oncology Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global gene therapy in oncology: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Bristol-Myers Squibb

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Cold Genesys

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Advantagene

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Amgen

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. AstraZeneca

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Bio-Path Holdings

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. CRISPR Therapeutics

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Editas Medicine

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Geron Corp

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Idera Pharmaceuticals

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Intellia Therapeutics

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Johnson & Johnson

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Marsala Biotech

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Merck

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Mologen AG

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Oncolytics Biotech

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Oncosec

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. Oncotelic

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

9.19. Shenzhen SiBiono GeneTech

9.19.1. Company Basic Information and Sales Area

9.19.2. Main Business/Business Overview

9.19.3. Product Portfolio

9.19.4. Financial

9.19.5. Recent Industry Insights

9.19.6. SWOT Analysis

9.20. Sillajen Biotherapeutics

9.20.1. Company Basic Information and Sales Area

9.20.2. Main Business/Business Overview

9.20.3. Product Portfolio

9.20.4. Financial

9.20.5. Recent Industry Insights

9.20.6. SWOT Analysis

9.21. Tocagen

9.21.1. Company Basic Information and Sales Area

9.21.2. Main Business/Business Overview

9.21.3. Product Portfolio

9.21.4. Financial

9.21.5. Recent Industry Insights

9.21.6. SWOT Analysis

9.22. UniQure

9.22.1. Company Basic Information and Sales Area

9.22.2. Main Business/Business Overview

9.22.3. Product Portfolio

9.22.4. Financial

9.22.5. Recent Industry Insights

9.22.6. SWOT Analysis

9.23. Ziopharm Oncology

9.23.1. Company Basic Information and Sales Area

9.23.2. Main Business/Business Overview

9.23.3. Product Portfolio

9.23.4. Financial

9.23.5. Recent Industry Insights

9.23.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global gene therapy in oncology Market

Figure 4: Global gene therapy in oncology Market: Drivers

Figure 5: Global gene therapy in oncology Market: Challenges

Figure 6: Global gene therapy in oncology Market: Trends

Figure 7: Global gene therapy in oncology Market: Opportunity

Figure 8: Global gene therapy in oncology Market: Restraint

Figure 9: Global gene therapy in oncology Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global gene therapy in oncology Market Value (USD Million) By Region

Figure 15: Global gene therapy in oncology Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global gene therapy in oncology Market Value (USD Million) By Region

Figure 23: Global gene therapy in oncology Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

99 items

Table 1: Market Segmentation Analysis

Table 2: Global gene therapy in oncology Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global gene therapy in oncology Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global gene therapy in oncology Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global gene therapy in oncology Market Value (USD Million) By Region

Table 10: Global gene therapy in oncology Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global gene therapy in oncology Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global gene therapy in oncology Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global gene therapy in oncology Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Bristol-Myers Squibb Basic Information And Sales Area

Table 31: Bristol-Myers Squibb. Products Portfolio

Table 32: Cold Genesys Basic Information And Sales Area

Table 33: Cold Genesys. Products Portfolio

Table 34: Advantagene Basic Information And Sales Area

Table 35: Advantagene. Products Portfolio

Table 36: Amgen Basic Information And Sales Area

Table 37: Amgen. Products Portfolio

Table 38: AstraZeneca Basic Information And Sales Area

Table 39: AstraZeneca. Products Portfolio

Table 40: Bio-Path Holdings Basic Information And Sales Area

Table 41: Bio-Path Holdings. Products Portfolio

Table 42: CRISPR Therapeutics Basic Information And Sales Area

Table 43: CRISPR Therapeutics. Products Portfolio

Table 44: Editas Medicine Basic Information And Sales Area

Table 45: Editas Medicine. Products Portfolio

Table 46: Geron Corp Basic Information And Sales Area

Table 47: Geron Corp. Products Portfolio

Table 48: Idera Pharmaceuticals Basic Information And Sales Area

Table 49: Idera Pharmaceuticals. Products Portfolio

Table 50: Intellia Therapeutics Basic Information And Sales Area

Table 51: Intellia Therapeutics. Products Portfolio

Table 52: Johnson & Johnson Basic Information And Sales Area

Table 53: Johnson & Johnson. Products Portfolio

Table 54: Marsala Biotech Basic Information And Sales Area

Table 55: Marsala Biotech. Products Portfolio

Table 56: Merck Basic Information And Sales Area

Table 57: Merck. Products Portfolio

Table 58: Mologen AG Basic Information And Sales Area

Table 59: Mologen AG. Products Portfolio

Table 60: Oncolytics Biotech Basic Information And Sales Area

Table 61: Oncolytics Biotech. Products Portfolio

Table 62: Oncosec Basic Information And Sales Area

Table 63: Oncosec. Products Portfolio

Table 64: Oncotelic Basic Information And Sales Area

Table 65: Oncotelic. Products Portfolio

Table 66: Shenzhen SiBiono GeneTech Basic Information And Sales Area

Table 67: Shenzhen SiBiono GeneTech. Products Portfolio

Table 68: Sillajen Biotherapeutics Basic Information And Sales Area

Table 69: Sillajen Biotherapeutics. Products Portfolio

Table 70: Tocagen Basic Information And Sales Area

Table 71: Tocagen. Products Portfolio

Table 72: UniQure Basic Information And Sales Area

Table 73: UniQure. Products Portfolio

Table 74: Ziopharm Oncology Basic Information And Sales Area

Table 75: Ziopharm Oncology. Products Portfolio

Table 76: Global Market Value (USD Million) (2025-2032) By Application

Table 77: Global Market Share (%) By Application (2032)

Table 78: Global Market Value (USD Million) (2025-2032) By Types

Table 79: Global Market Share (%) By Types (2032)

Table 80: Global gene therapy in oncology Market Value (USD Million) By Region

Table 81: Global gene therapy in oncology Market Share (%) By Region (2025-2032)

Table 82: North America Market Value (USD Million) (2025-2032) By Country

Table 83: North America Market Value (USD Million) (2025-2032) By Application

Table 84: North America Market Value (USD Million) (2025-2032) By Types

Table 85: Europe Market Value (USD Million) (2025-2032) By Country

Table 86: Europe Market Value (USD Million) (2025-2032) By Application

Table 87: Europe Market Value (USD Million) (2025-2032) By Types

Table 88: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 89: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 90: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 91: South America Market Value (USD Million) (2025-2032) By Country

Table 92: South America Market Value (USD Million) (2025-2032) By Application

Table 93: South America Market Value (USD Million) (2025-2032) By Types

Table 94: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 95: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 96: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 97: Research Programs/Design For This Report

Table 98: Key Data Information From Secondary Sources

Table 99: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

gene therapy in oncology Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.80 million
Revenue forecast in 2033	48.77 million
Growth rate	CAGR of 18.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; Europe; Asia Pacific; Latin America; MEA
Country scope	U.S.; Canada; Mexico; UK; Germany; France; China; India; Japan; Australia; South Korea; Brazil; UAE; Saudi Arabia; South Africa
Key companies profiled	Bristol-Myers Squibb; Cold Genesys; Advantagene; Amgen; AstraZeneca; Bio-Path Holdings; CRISPR Therapeutics; Editas Medicine; Geron Corp; Idera Pharmaceuticals; Intellia Therapeutics; Johnson & Johnson; Marsala Biotech; Merck; Mologen AG; Oncolytics Biotech; Oncosec; Oncotelic; Shenzhen SiBiono GeneTech; Sillajen Biotherapeutics; Tocagen; UniQure; Ziopharm Oncology
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Advances in gene editing technologies such as CRISPR/Cas9 are enabling the development of more effective and targeted cancer treatments, driving growth in the gene therapy in oncology market.

Increasing investment in research and development by pharmaceutical companies and biotech firms is fueling innovation and expansion in the gene therapy in oncology market.

Restraints2 items

High development costs and regulatory hurdles are significant barriers to entry for new companies, limiting the growth forecast of the gene therapy in oncology market.

The complexity of gene therapy and the need for specialized manufacturing and delivery systems are also constraining factors in the gene therapy in oncology market.

Opportunities2 items

Challenges2 items

Ensuring the safety and efficacy of gene therapies is a significant challenge, requiring rigorous testing and regulatory approvals.

The high cost of gene therapies and issues related to patient access and reimbursement are also major challenges facing companies in the gene therapy in oncology market.

Market Segmentation

Loading chart…

gene therapy in oncology Segmentation Breakdown7 items

Application

Hospitals

Diagnostics Centers

Research Institutes

Types

Ex Vivo

In Vivo

Regional Insights

Loading chart…

Key Drivers by Region5 items

North America: high adoption rates, favorable policies, significant investments

Europe: mature ecosystem, high infrastructure quality, growing demographics

Asia Pacific: increasing investments, improving infrastructure, large demographics base

Latin America: rising adoption rates, growing policies support, expanding ecosystem maturity

Middle East & Africa: growing adoption rates, improving infrastructure, increasing policies support

Competitive Landscape

Bristol-Myers Squibb: regional expansion

Cold Genesys: innovation pipeline

Advantagene: local manufacturing

Amgen: premium pricing

AstraZeneca: OEM tie-ups

CRISPR Therapeutics: vertical integration

Key gene therapy in oncology Companies23 items

Bristol-Myers Squibb

Cold Genesys

Advantagene

Amgen

AstraZeneca

Bio-Path Holdings

CRISPR Therapeutics

Editas Medicine

Geron Corp

Idera Pharmaceuticals

Intellia Therapeutics

Johnson & Johnson

Marsala Biotech

Merck

Mologen AG

Oncolytics Biotech

Oncosec

Oncotelic

Shenzhen SiBiono GeneTech

Sillajen Biotherapeutics

Tocagen

UniQure

Ziopharm Oncology

Market Ecosystem

Technology providers — develop gene therapy technologies

Raw material/component suppliers — provide essential materials

OEMs / manufacturers — produce gene therapy products

System integrators / EPCs — integrate gene therapy solutions

Distributors / channel partners — facilitate product distribution

Regulators/standards bodies — oversee safety and efficacy standards

End users / buyers — receive gene therapy treatments

Recent Industry Insights

Analyst Overview

Table of Contents